Find your next paid study

~$150 – $4,500

Actual pay is set by the research site.

BayerNCT05099172

Chronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSmall Lymphocytic Lymphoma

Phase 2 Study of Time-Limited BGB-16673 and Sonrotoclax With MRD-Guided Addition of Obinutuzumab for Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

This phase II trial tests how well tacabrutideg and sonrotoclax, with response-guided addition of obinutuzumab, works in treating patients with chronic lymphoc…

Fred Hutchinson Cancer CenterNCT07887061

~$75 – $2,000

Actual pay is set by the research site.

Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer

A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of …

~$75 – $3,000

Actual pay is set by the research site.

PfizerNCT04606446

Neoplasms, Solid TumorBreast Neoplasms, Triple-NegativeSquamous Cell Carcinoma of Skin+4 more

A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors

The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help de…

Onchilles Pharma IncNCT07339176

~$150 – $4,200

Actual pay is set by the research site.

Non Small Cell Lung CancerGlioma Glioblastoma MultiformeGlioma, Malignant+4 more

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP l…

Tango Therapeutics, Inc.NCT06810544

~$150 – $4,200

Actual pay is set by the research site.

Observational

Effect of Adjunctive Photobiomodulation on Mechanical Allodynia and Postoperative Pain Following Nonsurgical Root Canal Treatment in Teeth With Symptomatic Apical Periodontitis

This randomized, double-blind controlled clinical trial will evaluate whether adjunctive photobiomodulation improves recovery after nonsurgical root canal trea…

Symptomatic Apical PeriodontitisPostoperative PainMechanical Allodynia

University of MinnesotaNCT07886723

~$10 – $750

Actual pay is set by the research site.

Non-small Cell Lung Cancer

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and p…

~$75 – $3,000

Actual pay is set by the research site.

AstraZenecaNCT05061550

Non-small Cell Lung Cancer

A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non…

~$75 – $3,000

Actual pay is set by the research site.

Teligene USNCT05168566

Recurrent Small Cell Lung CancerExtensive-Stage Small Cell Lung CancerSmall Cell Lung Cancer+6 more

A Phase I Study to Assess the Safety and Antitumor Activity of Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

Background: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that …

National Cancer Institute (NCI)

~$150 – $2,700

Actual pay is set by the research site.

LiposarcomaProstate CancerAdvanced Breast Cancer+2 more

A PHASE 1/2A STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 adm…

~$150 – $4,500

Actual pay is set by the research site.

PfizerNCT04557449

Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors

This phase II trial studies the side effects of durvalumab when given together with chemotherapy in treating patients with solid tumors that have spread to oth…

National Cancer Institute (NCI)NCT03907475

~$75 – $1,800

Actual pay is set by the research site.

Phase 3

A Phase 3, Randomized, Open-label Study of Raludotatug Deruxtecan (MK-5909, R-DXd) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced Non-HRD-Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (ENGOT-ov102/MITO/GOG-3141/ REJOICE-Ovarian 04)

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible.…

Ovarian CancerOvarian NeoplasmsPeritoneal Cancer+1 more